2021 anti-cancer drug medical insurance price summary and inventory

A few days ago, the 2020 new version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" has been officially implemented.

At present, the medical insurance payment prices of corresponding drugs have been released one after another.

Image source: Dongdong Cancer Friends Circle

Four major domestic PD-1

Compared with previous years, the number of drugs transferred into the medical insurance catalog in 2020 is the largest.

Specifically, tislelizumab was reduced to RMB 2,180 per tube (100 mg), and the annual treatment cost after medical insurance was reimbursed was less than RMB 75,000; carrelizumab was reduced to RMB 2,928 per tube (200 mg).

At the same time, all indications currently approved for these 4 products, including Hodgkin's lymphoma, urothelial carcinoma, melanoma, hepatocellular carcinoma, non-squamous non-small cell lung cancer, and esophageal squamous cell carcinoma, can be reimbursed by medical insurance.

It is worth mentioning that tislelizumab has brought about 1.

Similarly, Teriplimumab is predicted to be around 1.

Heavy liver cancer targeted drug-lenvatinib

The new medical insurance catalogue finally included the new targeted drug lenvatinib.

Compared with sorafenib in 2008, lenvatinib, which was launched in November 2018, is the only new first-line treatment for liver cancer approved in the Chinese market in ten years.

Included in the medical insurance catalog this time, the price of lenvatinib has been reduced by 80.

The first new drug to go overseas-Zebutinib

As the only FDA-approved BTK inhibitor that can achieve a median 100% share in peripheral blood cells, and the only BTK inhibitor that can be taken once or twice a day, as well as China’s first new overseas drug, Zebutinib is in It was included in the medical insurance in the first year after listing, and its indications include mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma.

The price of Zebutinib before the medical insurance was 11,300 yuan per box (80 mg, 64 tablets), this time the medical insurance was reduced to 6336 yuan per box.

First-line treatment included in medical insurance-osimertinib

As a therapeutic drug targeting lung cancer, the largest group of patients in China, the third-generation EGFR-TKI drug osimertinib has attracted much attention.

Osimertinib covers the first-line and second-line indications of EGFR mutations, and solves the problem of targeted drug resistance in the first two generations, which can significantly extend the progression-free survival of patients.

The price of osimertinib when it first entered the country was 53,000 yuan/box, which was reduced to 15,300 yuan/box after medical insurance negotiations in 2018, and this time it was reduced to 5580 yuan on the basis of 15,300 yuan.

In addition, the first domestically produced third-generation lung cancer targeted drug Ametinib was also included in the medical insurance, and the price was reduced by 64% to 3,520 yuan per box.

New drug for ovarian cancer-Nirapali

As Zai Lab's first commercialized product, niraparib (Zera) is the only new ovarian cancer new drug included in the 2020 drug catalog, and it is also the first national Class 1 new drug PARP inhibitor.
The drug will be released in 2020.
The annual sales revenue was 32.
138 million U.
S.
dollars, compared with 6.
625 million U.
S.
dollars in 2019, a nearly 5-fold increase.

Nirapali is included in the indication for maintenance treatment of platinum-sensitive relapsed ovarian cancer.
The average monthly treatment cost before medical insurance is about 25,000 yuan.
After the medical insurance is included, the price drops to 5778 yuan per box.
The minimum monthly fee is only about 3,000 yuan.

In addition, Olapali, which is also a PARP inhibitor, has also entered the medical insurance catalog again.
Its indications are first-line maintenance treatment and second-line treatment of ovarian cancer.
The price is 5712 yuan/box, which is similar to the former.

Expansion of reimbursement-Anlotinib

Anlotinib invested 1 billion yuan and self-developed after 11 years of independent research and development by CP Tianqing is the first approved third-line treatment drug for advanced non-small cell lung cancer in China and the only approved third-line treatment drug for advanced non-small cell lung cancer in the world.
It is also the only targeted drug recommended in the third-line treatment guidelines for lung cancer.
.

Although Anlotinib entered the medical insurance as early as 2019, it is only indicated for the third-line treatment of advanced non-small cell lung cancer.
This time the medical insurance indications of the drug have been expanded, with the third-line treatment for small cell lung cancer and the second-line treatment for advanced soft tissue sarcoma.
Are included.

Anlotinib has continued to increase its volume since its launch, and its sales in 2020 are expected to be between 4 billion and 4.
5 billion yuan.
At the same time, it has been newly approved this year for the indication of medullary thyroid cancer.
Based on its dual effects of inhibiting tumor growth and anti-tumor angiogenesis, Anlotinib shows a certain broad-spectrum anti-tumor ability, and the market is expected to further expand in the future.

The world's first RANKL inhibitor-desulumab

As the world's first RANKL inhibitor, Disuzumab was successfully selected into the 2020 medical insurance catalogue.
Bone is the most common metastatic site for malignant tumors other than the lung and liver.
About 70%-80% of patients with malignant tumors will eventually develop bone metastases.
Based on the safety and efficacy of traditional drugs such as zoledronic acid, this time It can be said that the entry of disulumab into medical insurance is well-received.

The price of disulumab is reduced by about 80% to RMB 1,060 per tube, which will further reduce the economic burden of patients with giant cell tumor of bone, and greatly improve the quality of life of patients through the prevention and control of bone-related events related to cancer bone metastasis.